Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> c-Kit

c-Kit

C-kit is a type of receptor tyrosine kinase and a type of tumor marker, also called CD117 and stem cell factor receptor.

Products for  c-Kit

  1. Cat.No. Product Name Information
  2. GC18167 AC710

    A potent and selective PDGFR family inhibitor

     AC710 Chemical Structure
  3. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

     A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56) Chemical Structure
  4. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)

    MP470 hydrochloride; HPK 56 hydrochloride

     Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride) Chemical Structure
  5. GC14292 Apatinib Mesylate

    YN968D1

     Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization. Apatinib Mesylate Chemical Structure
  6. GC10914 AST 487

    NVP-AST 487

     A multi-kinase inhibitor AST 487 Chemical Structure
  7. GC19074 Avapritinib

    Avapritinib

     Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. Avapritinib Chemical Structure
  8. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  9. GC33027 AZD3229 An inhibitor of c-Kit-driven cell proliferation AZD3229 Chemical Structure
  10. GC33246 AZD3229 Tosylate AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 Tosylate Chemical Structure
  11. GC68727 Barzolvolimab

    CDX 0159

    Barzolvolimab (CDX 0159) is a humanized monoclonal antibody against KIT IgG1. Barzolvolimab specifically and effectively inhibits the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria.

     Barzolvolimab Chemical Structure
  12. GC64810 Bezuclastinib

    CGT9486; PLX 9486

     Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 Bezuclastinib Chemical Structure
  13. GC19106 c-Kit-IN-1 c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM. c-Kit-IN-1 Chemical Structure
  14. GC35705 c-Kit-IN-2 c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively. c-Kit-IN-2 Chemical Structure
  15. GC38595 c-Kit-IN-3 c-Kit-IN-3 Chemical Structure
  16. GC38756 c-Kit-IN-3 D-tartrate c-Kit-IN-3 D-tartrate Chemical Structure
  17. GC38757 c-Kit-IN-3 hydrochloride c-Kit-IN-3 hydrochloride Chemical Structure
  18. GC65948 c-Kit-IN-5-1 c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties. c-Kit-IN-5-1 Chemical Structure
  19. GC15779 Cabozantinib (XL184, BMS-907351)

    BMS-907351, Cabozantinib

     Cabozantinib (XL184, BMS-907351) is an orally bioavailable and potent inhibitor of MET and VEGFR2 with IC50 values of 1.3nM and 0.035nM, respectively. Cabozantinib (XL184, BMS-907351) Chemical Structure
  20. GC62145 Chiauranib

    CS2164

     Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib Chemical Structure
  21. GC35682 CHMFL-ABL/KIT-155

    CHMFL-ABL-KIT-155

     CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis. CHMFL-ABL/KIT-155 Chemical Structure
  22. GC35685 CHMFL-KIT-033 CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM. CHMFL-KIT-033 Chemical Structure
  23. GC25313 CS-2660 (JNJ-38158471) CS-2660 (JNJ-38158471) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50 of 40 nM. CS-2660 (JNJ-38158471) also inhibits closely related tyrosine kinases such as RET (c-RET) and Kit (c-Kit) with IC50 of 180 nM and 500 nM，while it has no significant activity (>1 microM) against VEGFR-1 and VEGFR-3. CS-2660 (JNJ-38158471) Chemical Structure
  24. GC11171 DCC-2618

    DCC2618;DCC 2618

     A dual inhibitor of c-Kit and c-MET DCC-2618 Chemical Structure
  25. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  26. GC69050 Elenestinib

    BLU-263

    Elenestinib (BLU-263) is an effective orally active inhibitor of tyrosine kinase. Elenestinib has the potential to study systemic mastocytosis (SM).

     Elenestinib Chemical Structure
  27. GC32867 Flumatinib (HHGV678)

    HH-GV-678

     Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678) Chemical Structure
  28. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate Chemical Structure
  29. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571) Chemical Structure
  30. GC60930 Imatinib D4 Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D4 Chemical Structure
  31. GC39612 Imatinib D8 Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D8 Chemical Structure
  32. GC11759 Imatinib Mesylate (STI571)

    CGP57148B, STI571

     Imatinib Mesylate (STI571) is an orally bioavailable multi-target inhibitor with IC50 values for Bcr-Abl, c-Kit and PDGFR are 0.6μM, 0.1μM and 0.1μM respectively. Imatinib Mesylate (STI571) Chemical Structure
  33. GC13961 ISCK03

    c-Kit Inhibitor II,Stem-Cell Factor/c-Kit Inhibitor

     inhibitor of SCF-mediated c-kit activation ISCK03 Chemical Structure
  34. GC13264 Ki20227

    Ki 20227;Ki-20227

     A c-Fms kinase inhibitor Ki20227 Chemical Structure
  35. GC73672 Labuxtinib Labuxtinib is c-kit tyrosine kinase inhibitor. Labuxtinib Chemical Structure
  36. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

     E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.  Lenvatinib (E7080) Chemical Structure
  37. GC36438 Lenvatinib mesylate

    E-7080

     An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  38. GC17958 Linifanib (ABT-869)

    Linifanib

     Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  39. GC62314 M4205 M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. M4205 Chemical Structure
  40. GC13410 Masitinib (AB1010)

    AB-1010, Masican, Masiviera

     Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib (AB1010) Chemical Structure
  41. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  42. GC13012 Motesanib Motesanib Chemical Structure
  43. GC11336 Motesanib Diphosphate (AMG-706)

    Motesanib

     Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. Motesanib Diphosphate (AMG-706) Chemical Structure
  44. GC78798 NN3201 NN3201 is a c-Kit -targeting antibody-drug conjugate ( ADC ) with high affinity ( K D = 0.19 pM). NN3201 Chemical Structure
  45. GC14957 OSI-930 Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck OSI-930 Chemical Structure
  46. GC16327 Pazopanib (GW-786034)

    GSK-VEG10003, GW786034B

     A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  47. GC12730 Pazopanib Hydrochloride

    GW786034;Votrient;Armala;GW 786034;GW-786034

     VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  48. GC72911 Pazopanib-13C,d3 hydrochloride

    GW786034-13C,d3 hydrochloride

     Pazopanib-13C,d3 (drochloride) is the deuterium and 13C labeled Pazopanib drochloride. Pazopanib-13C,d3 hydrochloride Chemical Structure
  49. GC12222 Pexidartinib (PLX3397)

    PLX3397

     Pexidartinib (PLX3397)is a potent, orally active, selective, and ATP-competitive CSF1R and c-Kit inhibitor, with IC50 values of 0.02μM and 0.01μM, respectively. Pexidartinib (PLX3397) Chemical Structure
  50. GC34708 Pexidartinib hydrochloride Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity. Pexidartinib hydrochloride Chemical Structure
  51. GC15075 PLX647 dual inhibitor of FMS and KIT kinases PLX647 Chemical Structure
  52. GC37538 Ripretinib

    DCC-2618

     Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. Ripretinib Chemical Structure
  53. GC19332 Sitravatinib

    MGCD-516

     Sitravatinib is a tyrosine kinase inhibitor (TKI) that targets the TYRO3, AXL, and MERTK (TAM) receptors, the vascular endothelial growth factor receptor (VEGFR) family, c-Kit, and c-MET. Sitravatinib Chemical Structure
  54. GC14733 SU14813

    SU-14813;SU 14813

     A dual VEGFR and PDGFR family kinase inhibitor SU14813 Chemical Structure
  55. GC14315 SU14813 maleate A dual VEGFR and PDGFR family kinase inhibitor SU14813 maleate Chemical Structure
  56. GC15254 Tandutinib (MLN518)

    CT 53518, MLN518

     Tandutinib (MLN518) (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib (MLN518) can be used for acute myelogenous leukemia (AML). Tandutinib (MLN518) has the ability to cross the blood-brain barrier. Tandutinib (MLN518) Chemical Structure
  57. GC38853 Tandutinib hydrochloride

    MLN518 hydrochloride; CT53518 hydrochloride

     Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier. Tandutinib hydrochloride Chemical Structure
  58. GC11763 Telatinib (BAY 57-9352)

    BAY 579352;BAY 57 9352

     Telatinib (BAY 57-9352) (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively. Telatinib (BAY 57-9352) Chemical Structure
  59. GC10719 Toceranib

    PHA 291639, SU11654

     A multi-targeted receptor tyrosine kinase inhibitor Toceranib Chemical Structure
  60. GC37808 Toceranib phosphate Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors . Toceranib phosphate Chemical Structure

59 Item(s)

per page

Set Descending Direction